1687 / 2063
ESTRO
2017
Combined chemo- and radiotherapy
treatment
• “Objective-oriented” design of clinical trials
• Benefit of RT+Chemo is due to tissular interaction
• Anti-proliferation-based efficacy and toxicity
• More data needed to design combined RT+Chemo
trial based on cellular/molecular interaction
• Equal dose trial <> equal toxicity trial